Core Viewpoint - MiniMed Group, Inc. has announced the pricing of its initial public offering (IPO) at $20.00 per share, with 28,000,000 shares available for public trading on Nasdaq starting March 6, 2026 [1] Group 1: IPO Details - The IPO is expected to close on March 9, 2026, subject to customary closing conditions [1] - MiniMed has granted underwriters a 30-day option to purchase up to 4,200,000 additional shares at the initial price [1] - Upon completion of the IPO, Medtronic is expected to hold approximately 90.03% of MiniMed, or 88.70% if the over-allotment option is fully exercised [1] Group 2: Use of Proceeds - MiniMed intends to use a portion of the net proceeds for general corporate purposes [1] - The remainder will be used to repay intercompany debt owed to Medtronic and as additional consideration for certain assets transferred to MiniMed [1] Group 3: Company Background - MiniMed is a global leader in insulin delivery, providing integrated ecosystems for diabetes management in 80 countries [1] - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company addressing significant health challenges [1]